telomirpharma.com - TELO Company profit before taxes, interest and amortization
The expansion of the small molecule pipeline for telomere control at Telomir Pharmaceuticals (TELO) stimulates strict oversight of chemical formula delivery to laboratories. Aggregate EBITDA clearly confirms this correlation, where 0.00 shows the value of this parameter. The result is the creation of a comprehensive longevity ecosystem that radically transforms methods for treating age-related pathologies and bodily recovery.
Telomir Pharmaceuticals, Inc. - analytical breakdowns and key metrics (TELO)
- market value and analyst target forecast:
- issuer market value details:
- issuer book value statistics:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Telomir Pharmaceuticals|TELO - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Telomir Pharma|TELO - Company Aggregate Debts|Debts to Book Value Telomir Pharmaceuticals Inc|TELO - Company Long-Term Debt|Company Short-Term Debt Telomir Pharmaceuticals|Immediate Liquidity telomirpharma.com
- earnings and market ratios statistics:
TELO - Company Net Income|Future Profit Telomir Pharmaceuticals|TELO - P/E Multiple|Market Cap to Projected Earnings Telomir Pharmaceuticals Inc|TELO - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Telomir Pharma|TELO - Operating profit before deduction of amortization|Earnings per share for the trailing year Telomir Pharmaceuticals|TELO - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months telomirpharma.com|TELO - Earnings growth in current year|Expected earnings per share trend next year Telomir Pharmaceuticals
- sales revenue and business income indicators:
Summary company analytics:Telomir Pharmaceuticals
This indicator is calculated as the difference between daily revenue from core operations and direct operating expenses, allowing for an assessment of the business's real liquidity excluding debt obligations. An analysis of operating cash flow before interest and taxes confirms the effectiveness of the outsourcing strategy at Telomir Pharmaceuticals (TELO), minimizing capital expenditures on laboratories and reducing the risk of capital drawdown during the scaling of research.
Competitors of Telomir Pharmaceuticals (TELO)
Company profit before taxes, interest and amortization HLN (Haleon plc)|KVUE: Operating profit before deduction of amortization|Verona Pharma - Company profit before taxes, interest and amortization|MENS: Operating profit EBITDA|Ligand Pharma - Income before deduction of interest, taxes and amortization|AMRX (Amneal Pharmaceuticals, Inc.) - Operating profit EBITDA|Profit before interest, taxes and amortization perrigo.com PRGO|Profit before payment of interest, taxes and amortization Alvotech SA (ALVO)|LQDA (Liquidia Corp) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA GLPG (Galapagos N.V.)|Operating profit EBITDA ANI Pharmaceuticals Corp ANIP|Afrezza - Operating profit EBITDA|amphastar.com (AMPH) - Operating profit before deduction of amortization|PCRX: Operating profit EBITDA|SPRY - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Theravance|Profit before interest, taxes and amortization Aquestive Corp AQST|Operating profit EBITDA SCPH|TECX - Profit before interest, taxes and amortization|Tonix Pharmaceuticals Holding Corp. - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization SXTC|Eupraxia Pharmaceuticals, Inc. - Operating profit EBITDA|BHST: Profit before payment of interest, taxes and amortization|invizyne.com (EXOZ) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization ORMP (Oramed)|ENTX (Entera Bio) - Operating profit EBITDA|HYFT: Income before deduction of interest, taxes and amortization|Operating profit EBITDA ABVC|Cumberland Pharmaceuticals - Operating profit before amortization|Profit before payment of interest, taxes and amortization Quantum BioPharma Ltd. QNTM|FGEN: Operating profit before amortization|Rani Therapeutics Inc - Operating profit EBITDA|Income before deduction of interest, taxes and amortization SNYR (synergychc.com)|Rallybio (RLYB) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Lexaria Bioscience Corp|Operating profit before deduction of amortization PULM|PTHL - Operating profit before depreciation charges|Operating profit EBITDA APM|Operating income before deduction of amortization Lyra Therapeutics|Profit before payment of interest, taxes and amortization Impact BioMedical Inc IBO|TNFA - Operating profit before deduction of amortization|cbdMD, Inc. - Operating profit EBITDA|Income before deduction of interest, taxes and amortization PRFX (PainReform Ltd.)|CYTO (altamiratherapeutics.com) - Operating profit before deduction of amortization|LIPO: Company profit before taxes, interest and amortization|OPTN (Optinose) - Operating profit EBITDA|Operating profit before deduction of amortization Pieris (PIRS)|Profit before payment of interest, taxes and amortization Procaps Group S.A. (PROC)|Operating profit EBITDA petrospharma.com (PTPI)|Profit before payment of interest, taxes and amortization Qilian International Holding QLI|Income before deduction of interest, taxes and amortization SLRN|TFF Pharmaceuticals, Inc. - Operating profit EBITDA
